Trials / Completed
CompletedNCT02097173
Bioavailability in Patient With Psoriasis: Metoject Prefilled Pen
Relative Bioavailability of Methotrexate (MTX) 50 mg/mL Administered Subcutaneously (SC) by a Disposable Autoinjector (Metoject® Prefilled Pen) Compared With Intramuscular (IM) Administration of the United States Reference Listed Drug Methotrexate Injection (USP 25 mg/mL [Hospira]) in Patients With Psoriasis
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 35 (actual)
- Sponsor
- medac GmbH · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
This study is conducted to assess the relative bioavailability of MTX administered subcutaneously via a prefilled pen (50mg/mL) compared with MTX administered via IM injection (25mg/mL).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Methotrexate |
Timeline
- Start date
- 2013-05-01
- Primary completion
- 2013-10-01
- First posted
- 2014-03-26
- Last updated
- 2015-03-17
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02097173. Inclusion in this directory is not an endorsement.